1. Home
  2. Live Updates
  3. EQS-Adhoc: Formycon announces binding Term Sheet between Kli

EQS-Adhoc: Formycon announces binding Term Sheet between Kli

EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States Seite 1

09.01.2023 - EQS-Ad-hoc: Formycon AG / Key word(s): Agreement/Alliance Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States ... Seite 1

Related Keywords

United States , Munich , Bayern , Germany , Klinge Biopharma , Coherus Biosciences , Klinge Biopharma Gmbh , Coherus Biosciences Inc , Drug Administration , Term Sheet , Biologics License Application , Formycon ,

© 2025 Vimarsana